Efficacy and safety of solifenacin in the treatment of patients with bladder spasm after transurethral resection of prostate: a systematic review and meta-analysis

Objective To systematically review the efficacy and safety of solifenacin in the treatment of patients with bladder spasm after transurethral resection of prostate based on current evidence. Methods We searched Pubmed, EMbase, the Cochrane Library, CBM, CNKI, VIP and Wanfang Database from the establishment to October 2016 for the published literature on the treatment of patients with bladder spasm after transurethral resection of prostate with solifenacin.Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies.Then, meta-analysis was performed using RevMan 5.3 software. Results A total of 11 RCTs involving 621 patients were included.The results of meta-analysis showed that: compared with the no-solifenacin group(n=311), the numbers of bladder spasm episodes[MD=-1.38, 95%CI(-1.97, -0.97)P<0.00001], duration of bladder spasm[MD=-0.26, 95%CI(-0.41, -0.11), P=0.0008], the time of bladder perfusion clearance[MD=-0.59, 95%CI(-0.88, -0.29), P<0.0001], indwelling catheter delivery[MD=-0.29, 95%CI(-0.48, -0.11), P=0.09]in solifenacin group(n=310) reduced significantly, and there was no statistical difference in the incidence of overall adverse events between the two groups[RR=0.71, 95%CI(0.17, 2.98), P=0.64]. Conclusion Current evidence indicates that solifenacin is more effective and safe in the treatment of patients with bladder spasm after transurethral resection of prostate.Due to the limited quantity and quality of the include studies, more high quality studies are needed to verify the above conclusion. Key words: Urinary reservoirs, continent; Transurethral resection of prostate; Meta-analysis; Solifenacin